| DOJOLVI ULTRAGENYX PHARMACEUTICAL INC.
1995744 12 Sep 2019 | on 02 Mar 2022 | Class 005 Class 005 Pharmaceutical Products Pharmaceuticals for use in treating genetic disorders, autosomal disorders, lysosomal storage disorders, energy deficiency disorders and enzyme disorders; pharmaceuticals for use in treating metabolic disorders, namely, diabetes, bulimia nervosa, anorexia, obesity and hypothyroidism, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, and anemia; pharmaceuticals for use in treating long-chain fatty acid oxidation disorders (LC-FAOD) | |